Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.

Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K

Diabetes technology & therapeutics30 Aug 2011Cited by 25 (Europe PMC)

PMID21877924DOI10.1089/dia.2011.0137PepBankPUB-21877924

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In Japanese patients with type 2 diabetes, liraglutide significantly reduced 24-h mean glucose levels.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide lowered average 24-hour blood sugar.
Peptide
Liraglutide
Outcome
Decrease24-h mean glucose level
Study
n = 20
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
Liraglutide not only significantly reduced 24-h mean glucose levels but also significantly improved all the indices for glycemic variation evaluated, which included SDs of 24-h glucose levels, mean amplitude of glycemic excursions (MAGE), and total area under the glucose fluctuation curve (AUC) for 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792401
02HumanNon-randomized trialEfficacy outcome
In Japanese patients with type 2 diabetes, liraglutide significantly improved the SD of 24-h glucose levels.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide reduced day-long swings in blood sugar.
Peptide
Liraglutide
Outcome
DecreaseSD of 24-h glucose levels
Study
n = 20
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
Liraglutide not only significantly reduced 24-h mean glucose levels but also significantly improved all the indices for glycemic variation evaluated, which included SDs of 24-h glucose levels, mean amplitude of glycemic excursions (MAGE), and total area under the glucose fluctuation curve (AUC) for 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792402
03HumanNon-randomized trialEfficacy outcome
In Japanese patients with type 2 diabetes, liraglutide significantly improved the mean amplitude of glycemic excursions.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide reduced the size of blood sugar swings.
Peptide
Liraglutide
Outcome
DecreaseMean amplitude of glycemic excursions (MAGE)
Study
n = 20
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
Liraglutide not only significantly reduced 24-h mean glucose levels but also significantly improved all the indices for glycemic variation evaluated, which included SDs of 24-h glucose levels, mean amplitude of glycemic excursions (MAGE), and total area under the glucose fluctuation curve (AUC) for 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792403
04HumanNon-randomized trialEfficacy outcome
In Japanese patients with type 2 diabetes, liraglutide significantly improved the total area under the glucose fluctuation curve for 24 h.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide reduced the overall day-long blood sugar load.
Peptide
Liraglutide
Outcome
Decrease24-h area under the glucose fluctuation curve
Study
n = 20
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
Liraglutide not only significantly reduced 24-h mean glucose levels but also significantly improved all the indices for glycemic variation evaluated, which included SDs of 24-h glucose levels, mean amplitude of glycemic excursions (MAGE), and total area under the glucose fluctuation curve (AUC) for 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792404
05HumanNon-randomized trialMechanism
In Japanese patients with type 2 diabetes, mean glucose, SD and AUC before treatment correlated negatively with their changes on liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, higher starting glucose values went with bigger falls on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of pre-treatment glucose indices with change on liraglutide
Study
n = 20
Comparator
Before treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
The study showed a significant negative correlation for mean glucose levels, SD, and AUC immediately before treatment versus their changes with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792405
06HumanNon-randomized trialOther
In 11 patients with type 2 diabetes treated with liraglutide monotherapy, an OGTT found normal glucose tolerance in six, impaired glucose tolerance in four and diabetes in one.
In plain wordsAfter liraglutide alone, a glucose test in 11 patients found most had normal or mildly impaired glucose tolerance.
Peptide
Liraglutide
Outcome
Not applicableGlucose tolerance status on OGTT after liraglutide monotherapy
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
A 75-g oral glucose tolerance test (OGTT) was given in 11 patients treated with liraglutide monotherapy once favorable glycemic control was achieved.
3 context sentences(design, population, supporting numbers)
Summary · context
The OGTT revealed that of these, six were found to have normal glucose tolerance, four had impaired glucose tolerance, and one had diabetes, and that of the six drug-naive patients, five patients were found to have normal glucose tolerance, and one had impaired glucose tolerance.
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792406
07HumanNon-randomized trialOther
In six drug-naive patients with type 2 diabetes treated with liraglutide monotherapy, an OGTT found normal glucose tolerance in five and impaired glucose tolerance in one.
In plain wordsAfter liraglutide alone, a glucose test in six drug-naive people with type 2 diabetes found five with normal glucose tolerance.
Peptide
Liraglutide
Outcome
Not applicableGlucose tolerance status on OGTT in drug-naive patients after liraglutide monotherapy
Study
n = 6
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg, then 0.6 mg, then 0.9 mg · 1-week intervals per doseAs given in this study (human).
Source sentences
Summary
The OGTT revealed that of these, six were found to have normal glucose tolerance, four had impaired glucose tolerance, and one had diabetes, and that of the six drug-naive patients, five patients were found to have normal glucose tolerance, and one had impaired glucose tolerance.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective open-label pilot study, a total of 20 type 2 diabetes patients hospitalized for glycemic control were given liraglutide 0.3 mg, followed by liraglutide 0.6 mg and 0.9 mg, with each given at 1-week intervals.
Summary · context
The patients were continuously monitored for their 24-h glucose levels before treatment and during the course of treatment with liraglutide 0.3 mg, 0.6 mg, and 0.9 mg, respectively, using continuous glucose monitoring (CGM).
Report a problemFND-2187792407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.